Drug intelligence / Profile preview

I-Falmin

Development stage
Unknown
Lead developer
Ismut Fitomedika
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

I-Falmin is a specialized nutraceutical and phytopharmaceutical candidate derived from the extract of the toman fish (*Channa micropeltes*), a species native to Southeast Asia known for its high protein and albumin content. The product is primarily utilized to address hypoalbuminemia and support recovery in patients suffering from chronic infections like pulmonary tuberculosis, malnutrition, and post-operative wounds. Its therapeutic profile is driven by concentrated levels of albumin, which helps maintain plasma oncotic pressure and serves as a carrier for various ligands, alongside essential amino acids and omega-6 fatty acids (such as arachidonic acid) that facilitate tissue repair and modulate immune responses. Developed by PT Ismut Fitomedika Indonesia, I-Falmin is currently registered as a traditional herbal medicine in Indonesia and is undergoing clinical evaluation (e.g., NCT07186478) to validate its efficacy as an adjunctive therapy for tuberculosis-associated nutritional recovery.

Brand names
IfalminI-Falmin
Other names
Channa micropeltes extractToman fish extractGiant snakehead extract

Beyond the preview

Go deeper on I-Falmin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-Falmin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call